Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
Public ClinicalTrials.gov record NCT03370185. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of Duvelisib Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi)
Study identification
- NCT ID
- NCT03370185
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- SecuraBio
- Industry
- Enrollment
- Not listed
Conditions and interventions
Interventions
- Duvelisib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 11, 2018
- Primary completion
- May 31, 2020
- Completion
- Feb 28, 2021
- Last update posted
- Feb 27, 2023
2018 – 2021
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology | Tempe | Arizona | 85284 | — |
| Genesis Cancer Center | Hot Springs | Arkansas | 71913 | — |
| Moores UC San Diego Cancer Center | La Jolla | California | 92093 | — |
| Ingalls Memorial Hospital | Harvey | Illinois | 60426 | — |
| QUEST Research Institute | Royal Oak | Michigan | 48073 | — |
| St. Vincent Frontier Cancer Center | Billings | Montana | 59102 | — |
| Summit Medical Group | Morristown | New Jersey | 07932 | — |
| Medical Oncology Associates PS, WA | Spokane | Washington | 99208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03370185, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 27, 2023 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03370185 live on ClinicalTrials.gov.